Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Ipilimumab 99 pembrolizumab 92 Nivolumab 84 Cyclophosphamide 69 fludarabine phosphate 55 aldesleukin 52 Interleukin-2 39 Dacarbazine 35 Vemurafenib 31 fludarabine 30 trametinib 29 dabrafenib 29 Temozolomide 28 Whole-Body Irradiation 21 Aminolevulinic Acid 21 Carboplatin 20 CTLA-4 Antigen 20 Bevacizumab 20 Peripheral Blood Stem Cell Transplantation 19 Radiotherapy 18 Radiosurgery 18 Tacrolimus 17 Mycophenolic Acid 17 Paclitaxel 16 HhAntag691 16 3-ingenyl angelate 16 Busulfan 15 Introns 14 Antilymphocyte Serum 14 encorafenib 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Tissue Array Analysis × Dermatologic × Clear all

NCT02236546 2017-04-13

FDG-PET in Advanced Melanoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated

3 enrolled 4 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡